DAIC's Top 10 for April

A look at DAIC's top-viewed content for April 2024

Getty Images

Clinical trials and innovative technology took center stage during the month of April, racking up some record number views. Here is a look at what DAIC viewers were reading last month:

1. New Study Reveals 65 and Older Population Lowered Blood Pressure, Cholesterol and Weight Using Mobile Technology

2. Atlantic Health System’s Morristown Medical Center Treats First Patient in New Jersey with Edwards’ EVOQUE Tricuspid Valve Replacement

3. Shorten the Blanking Period After Atrial Fibrillation Ablation, Experts Say

4. Medtronic Launches the Avalus Ultra Valve Engineered for Ease of Use at Implant and Lifetime Patient Management

5. Incentives Prompt Increased Daily Walking in Patients at Risk for Heart Disease

6. Novel CT Exam Reduces Need for Invasive Artery Treatment

7. FDA Announces Recalls of Abbott/Thoratec Corp. Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) Due to Long-term Buildup of biological material Causing an Obstruction

8. Around 10% of Deaths from Coronary Stenting, Balloon Angioplasty are Preventable

9. EMPACT-MI Trial Outcomes Reported at ACC.24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

10. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged

Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

News | FDA

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

June 18, 2024

Xeltis synthetic restorative pulmonary heart valve evolves into a fully functioning, natural heart valve through colonization by the patient’s own tissue.

News | FDA

Xeltis Receives IDE Approval from FDA for Initiation of US Pivotal Trial for aXess, its Restorative Vascular Access Conduit

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

June 13, 2024

Heuron ICH has received FDA 510(k) clearance

News | FDA

Heuron Gets FDA Green Light for Stroke Triage and Notification Solution

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

June 03, 2024

If you enjoy this content, please share it with a colleague

DAIC's Top 10 for April

If you enjoy this content, please share it with a colleague

Related Content